Darbepoetin alfa biosimilar (Biocad)

阿法达贝泊汀生物类似药 (Biocad)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDarbepoetin alfa biosimilar (Biocad)

Drug Alias Name阿法达贝汀生物仿制药 (Biocad)阿法达贝泊汀生物仿制药 (Biocad)达贝泊汀α生物仿制药 (Biocad)达促红素α生物仿制药 (Biocad)达依泊汀α生物仿制药 (Biocad) +[6]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionErythropoietin receptor agonists

TargetsErythropoietin receptor

Therapy Area/IndicationsAnemiaKidney Failure, ChronicRenal Insufficiency, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBIOCAD JSC

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBIOCAD JSC

Active IndicationsN/A

Inactive IndicationsAnemiaKidney Failure, ChronicRenal Insufficiency, Chronic

ATC CodeB03XA02